Shares in South Africa‘s Aspen Pharmacare fell more than 8% in early Friday trade a day after it forecast full-year revenue growth of between 1% and 4% in commercial pharmaceuticals. The drugmaker, which is in the process of disposing of its infant formula business, said in a statement that weaker performance across Europe had offset the positive performance for commercial pharmaceuticals in most emerging markets. At 0815 GMT, the shares were down 6.52% at R132.37($9.23). 